Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial
oleh: Daniel Mrak, Daniela Sieghart, Elisabeth Simader, Selma Tobudic, Helga Radner, Peter Mandl, Lisa Göschl, Maximilian Koblischke, Nikolaus Hommer, Angelika Wagner, Margareta Mayer, Lorenz Schubert, Lukas Hartl, Karin Kozbial, Philipp Hofer, Felix Kartnig, Thomas Hummel, Andreas Kerschbaumer, Thomas Deimel, Antonia Puchner, Venugopal Gudipati, Renate Thalhammer, Petra Munda, Keziban Uyanik-Ünal, Andreas Zuckermann, Gottfried Novacek, Thomas Reiberger, Erika Garner-Spitzer, Roman Reindl-Schwaighofer, Renate Kain, Stefan Winkler, Josef S. Smolen, Karin Stiasny, Gottfried F. Fischer, Thomas Perkmann, Helmuth Haslacher, Markus Zeitlinger, Ursula Wiedermann, Judith H. Aberle, Daniel Aletaha, Leonhard X. Heinz, Michael Bonelli
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2022-09-01 |
Deskripsi
Optimizing COVID-19 vaccination strategies for patients under immunosuppressive medication is of high importance. In this clinical trial including non-seroconverted immunosuppressed patients, a homologous mRNA booster vaccination resulted in higher seroconversion rate than a switch to a vector-based vaccine.